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To examine risk for mycosis among persons with sili-
cosis, we examined US mortality data for 1979–2004. Per-
sons with silicosis were more likely to die with pulmonary 
mycosis than were those without pneumoconiosis or those 
with more common pneumoconioses. Health profession-
als should consider enhanced risk for mycosis for silica-
exposed patients.
T
he pneumoconioses are a group of irreversible but 
preventable interstitial lung diseases, most commonly 
associated with inhalation of asbestos ﬁ  bers, coal mine 
dust, or crystalline silica dust. In response to inquiries 
from silica-exposed workers concerned about diagnoses 
of coccidioidomycosis or cryptococcal meningitis for their 
co-workers, we examined whether excess risk for mycosis 
exists among persons with silicosis. 
The Study
We examined mortality data from the National Center 
for Health Statistics of the Centers for Disease Control and 
Prevention, which are coded for causes of death reported 
on death certiﬁ  cates for all US residents according to the 
International Classiﬁ  cation of Diseases (ICD) (www.cdc.
gov/nchs/products/elec_prods/subject/mortmcd.htm). Be-
cause silicosis usually has a latency of >20 years, we re-
stricted our analyses to persons >45 years of age at death. 
We separately evaluated 3 groups of persons who had died 
with pulmonary mycosis coded as either the underlying or 
the contributing cause of death (any mention on death cer-
tiﬁ  cate) during 1979–2004: 1) those with any mention of 
silicosis versus no mention; 2) those with any mention of 
asbestosis versus no mention; and 3) those with any men-
tion of coal worker pneumoconiosis (CWP) versus no men-
tion. We excluded decedents with >2 pneumoconioses.
We analyzed mortality data for persons assigned the 
following ICD codes (9th revision [ICD-9] 1979–1998; 
10th revision [ICD-10] 1999–2004): 502/J62 (silicosis); 
501/J61 (asbestosis); 500/J60 (CWP); and 110–118/
B35–B49 (any mycosis). We deﬁ  ned pulmonary myco-
sis as death with ICD-9 and ICD-10 codes 112.4/B37.1 
(candidiasis); 114/B38.0, B38.1, B38.2, B38.9 (coccid-
ioidomycosis); 115/B39.0, B39.1, B39.2, B39.4, B39.9 
(histoplasmosis); 116.0/B40.0, B40.1, B40.2, B40.9 (blas-
tomycosis); 116.1/B41.0, B41.9 (paracoccidioidomyco-
sis); 117.1/B42.0, B42.9 (sporotrichosis); 117.7/B46.0, 
B46.5, B46.9 (zygomycosis); 117.3/B44.0, B44.1, B44.9 
(aspergillosis); 117.5/B45.0, B45.9 (cryptococcosis); and 
118/B48.7 (opportunistic mycoses). For many mycoses, 
ICD-9 codes do not differentiate pulmonary from other 
types of mycoses. For ICD-10 codes, we limited data to 
mycoses coded as pulmonary, opportunistic, and some 
unspeciﬁ  ed type of mycoses (e.g., B38.9, B39.4, B39.9, 
B40.9, B41.9, B42.9, B44.9, B45.9, B46.5, and B46.9). 
We provided results with and without ICD-9 code for op-
portunistic mycoses and ICD-10 codes for unspeciﬁ  ed 
mycoses and opportunistic mycoses.
We computed prevalence rate ratios and 95% con-
ﬁ  dence intervals (CIs) to separately compare pulmonary 
mycosis prevalence at death among persons with silicosis, 
asbestosis, and CWP with that for persons in the refer-
ent group and to compare pulmonary mycosis prevalence 
at death among persons with silicosis with that for per-
sons in the 2 pneumoconiosis comparison groups. Each 
ratio was computed by dividing the proportion of mycosis 
deaths in 1 group by the corresponding measure in the 
comparison group.
Decedents with pneumoconiosis and mycosis were 
rare, and most mycoses were pulmonary: 77% in persons 
with silicosis; 79% asbestosis, and 53% CWP (Table 1). 
Persons with silicosis were 4.5× (95% CI 3.4–6.0×) more 
likely to have any mycosis at death and 9.5× (95% CI 6.9–
13.1×) more likely to have pulmonary mycosis at death than 
were those without pneumoconiosis. Persons with silicosis 
were 2.9× (95% CI 1.9–4.4×) more likely than those with 
asbestosis and 6.7× (95% CI 4.3–10.5×) more likely than 
those with CWP to have pulmonary mycosis at death.
Among persons who died with pneumoconiosis, 
aspergillosis was the most common pulmonary mycosis. 
Those with silicosis were more likely than those without 
any pneumoconiosis to have aspergillosis, coccidioidomy-
cosis, or cryptococcosis at death (Table 2). Among the 48 
decedents who had silicosis and mycosis, 9 also had tuber-
culosis, 4 had diabetes (2 with tuberculosis), 2 had lung 
malignancy (1 with tuberculosis), and none had received 
organ transplants. From 1987 (the ﬁ  rst year of ICD codes 
for HIV) to 2004, 1 decedent with silicosis had HIV but not 
mycosis. Of 8 decedents with asbestosis and HIV, 2 had 
mycoses; no decedents with CWP had HIV. When we lim-
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ited analysis to decedents in the southwestern states (Ari-
zona, California, Nevada, New Mexico, Texas, and Utah), 
those with silicosis were 27.9× (95% CI 12.6–62.0×) more 
likely to have coccidioidomycosis at death than were de-
cedents without pneumoconioses, and those with asbes-
tosis were 4.5× (95% CI 1.9–10.8×) more likely to have 
coccidioidomycosis at death than were decedents without 
pneumoconioses. Decedents with silicosis from states bor-
dering the Ohio, Missouri, and Mississippi River valleys, 
were 4.8× (95% CI 0.7–34.0×) more likely to have histo-
plasmosis at death than were decedents without pneumo-
coniosis, and decedents with asbestosis were 3.9× (95% CI 
1.3–12.2×) more likely to have histoplasmosis than were 
decedents without pneumonconioses. 
Conclusions
We found that persons who die with silicosis are more 
likely to die with pulmonary mycosis than are those who 
die without pneumoconiosis or who die with the more com-
mon pneumoconioses. Insofar as silica dust impairs cellu-
lar defense, silica-exposed workers (without silicosis) may 
be at increased risk for fungal infections, as they are for 
mycobacterial infections (1).
Aspergillosis was the most common mycosis among 
persons with pneumoconiosis. Aspergillosis is a known 
complication in patients with underlying pulmonary dis-
ease, such as pulmonary tuberculosis and pneumoconiosis 
(2), in which silica-impaired macrophages are incapable 
of targeting inhaled conidia (3). The rarity of candidiasis 
in persons with silicosis may reﬂ  ect the fact that healthy 
workers are less likely to have concurrent diabetes or HIV 
infection.
Concurrent mycosis was speciﬁ  c to decedents with 
silicosis compared with those with asbestosis or CWP, pos-
sibly because coal mine dust and asbestos ﬁ  bers are less 
toxic to macrophages than are crystalline silica. Persons 
with asbestosis and CWP are also less commonly affected 
by autoimmune diseases and systemic immunologic com-
plications than are those with silicosis (4,5).
Direct impairment of macrophage function by crys-
talline silica and poor drug penetration into silicotic lung 
nodules have resulted in high (>20%) treatment failure and 
relapse rates for patients with silicosis who are receiving 
chemotherapy for tuberculosis (6). This ﬁ  nding has prompt-
ed prolonged and more aggressive treatment of tuberculo-
sis for such persons (7). Similarly, treatment of mycosis in 
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Table 1. Cause of death with any death certificate mention of selected pneumoconioses and mycoses (underlying or contributing 
cause), US residents >45 y of age, 1979–2004* 
Mycoses, no. (%)  Prevalence rate ratio† (95% CI) 
Any mention  Underlying cause  Any mention 
Cause No. deaths All Pulmonary All Pulmonary  All Pulmonary‡ 
Silicosis 6,723§ 48 (0.71)  37 (0.55)  25 (52)  21 (57)  4.5 (3.4–6.0)  9.5 (6.9–13.1) 
Asbestosis 23,899§ 58 (0.24)  46 (0.19)  22 (38)  18 (39)  1.5 (1.2–2.0)  3.3 (2.5–4.4) 
CWP 46,088§ 72 (0.16)  38 (0.08)  29 (40)  16 (42)  1.0 (0.8–1.2)  1.4 (1.0–2.0) 
All other deaths¶  51,677,216 81,699 (0.16)  29,914 (0.06)  33,941 (42) 12,982 (43)  NA NA
*Data from National Center for Health Statistics (www.cdc.gov/nchs/products/elec_prods/subject/mortmcd.htm). CI, confidence interval; CWP, coal worker 
pneumoconiosis; NA, not applicable.  
†Proportion of decedents with each selected pneumoconiosis who had mycosis coded as the underlying cause of death or as a contributing cause of 
death on the entity axis compared with the analogous proportion of pulmonary mycosis decedents without any mention of a selected pneumoconiosis as 
underlying cause of death or a contributing cause of death on the entity axis (all other deaths). 
‡When International Classification of Diseases (ICD) 9th or 10th revision codes for opportunistic mycoses and ICD-10 codes for unspecified types of 
mycoses were excluded, the prevalence rate ratio and 95% CI for deaths with any mention of silicosis became 10.4 (7.5–14.4); asbestosis 3.3 (2.4–4.4); 
and CWP 1.5 (1.1–2.1). 
§No. persons who died for which the selected pneumoconiosis was coded as the underlying cause of death or as a contributing cause of death on the 
entity axis, excluding decedents with multiple pneumoconioses. 
¶Excludes deaths with any mention (underlying or contributing cause) of silicosis, asbestosis, and/or CWP. 
Table 2. Cause of death for decedents with any death certificate mention of selected pneumoconioses (underlying or contributing
cause) and any mention of the most common types of pulmonary mycosis, US residents t45 y of age, 1979–2004* 
Pulmonary mycosis, prevalence rate ratio (95% CI) 
Cause Coccidioidomycosis† Histoplasmosis‡  Aspergillosis§  Cryptococcosis¶ 
Silicosis 17.9 (8.0–39.9) 2.9 (0.4–20.7)  13.9 (9.2 – 21.1) 6.9 (3.3 –14.5) 
Asbestosis 4.2 (1.8–10.1) 3.3 (1.2–8.8)  5.5 (3.9– 7.8) 0.8 (0.3–2.6) 
CWP 0 0.4 (0.1–3.0)  1.8 (1.2–2.9) 0.9 (0.4–1.9) 
*Compared with persons who died without any mention of selected pneumoconioses. Data from National Center for Health Statistics
(www.cdc.gov/nchs/products/elec_prods/subject/mortmcd.htm). CI, confidence interval; CWP, coal worker pneumoconiosis.  
†Six with coccidiodomycosis among 6,723 decedents with silicosis; 5 among 23,899 decedents with asbestosis; zero among 46,088 with CWP; 2,576 
among 51,677,216 without silicosis, asbestosis, and/or CWP. 
‡One with histoplasmosis among 6,723 decedents with silicosis; 4 among 23,899 with asbestosis; 1 among 46,088 with CWP; 2,633 among 51,677,216 
without silicosis, asbestosis, and/or CWP. 
§Twenty-two with aspergillosis among 6,723 decedents with silicosis; 31 among 23,899 with asbestosis; 20 among 46,088 with CWP; 12,165 among 
51,677,216 without silicosis, asbestosis, and/or CWP. 
¶Seven with cryptococcosis among 6,723 decedents with silicosis; 3 among 23,899 with asbestosis; 6 among 46,088 with CWP; 7,786 among 51,677,216 
without silicosis, asbestosis, and/or CWP. patients with silicosis or substantial past exposure to silica 
dust may require prolonged treatment and possibly chronic 
suppressive antifungal therapy, as is used for patients with 
immunocompromised conditions (8).
Lacking population-based surveillance data for sili-
cosis and mycosis illness and silica exposures, we relied 
on death certiﬁ  cate data, which have limitations; e.g., only 
≈1 of 6 persons who had silicosis had silicosis recorded as 
a cause of death on the death certiﬁ  cate (9). Also, many 
persons with substantial exposure to silica dust never re-
ceive a diagnosis of silicosis. We were unable to address 
the question of possible increased risk for mycosis among 
silica-exposed persons, and our analysis may underrep-
resent the actual extent of concurrent silicosis and my-
cosis. Another limitation was use of ICD-9 and ICD-10 
coding for fungal infections and for fungal infection caus-
ing death. Sensitivity of this method can vary at different 
institutions and over time, especially if fungal infections 
are underdiagnosed. In addition, the ICD-9 classiﬁ  cation 
codes for many mycoses do not differentiate pulmonary 
from other types of mycoses.
Health professionals should consider enhanced risk 
for mycosis with regard to preventive interventions, differ-
ential diagnosis, and mycosis treatment of silica-exposed 
workers. Measures to protect silica-exposed workers with 
coexposure to fungi include reducing silica exposure; wet-
ting soil and bird droppings to suppress fungal-contaminat-
ed dust; maintaining good personal hygiene; and, in areas 
with endemic inhaled fungi, using enclosed operator cabs 
with high-efﬁ  ciency particulate air ﬁ  ltration or personal re-
spiratory protection for particulates (10).
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